Rockville’s Sanaria to test malaria vaccine

While Sanaria Inc. works to keep its focus on developing revenue streams, the estimated 3,000 children who die each day in a global resurgence of malaria add a humanitarian perspective for the Rockville company.

This week, Sanaria, headed by CEO Stephen Hoffman, begins manufacturing its first run of a unique and promising malaria vaccine. By spring, the company will have several thousand doses of the vaccine ready for testing its toxicity and dosage levels, paving the way for clinical trials to begin next January.